Thermo Fisher Scientific Inc
TMO · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B |
| Research & Development | $1.40B | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B | $1.00B | $967.00M |
| Selling, General & Administrative | $8.73B | $8.60B | $8.45B | $8.99B | $8.01B | $6.93B | $6.14B | $6.06B |
| Operating Expenses | $36.81B | $35.54B | $36.00B | $36.52B | $29.18B | $24.42B | $20.95B | $20.57B |
| Operating Income | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B |
| Interest Expense | — | — | $1.38B | $726.00M | $536.00M | $553.00M | $676.00M | $667.00M |
| Other Income / (Expense) | -$12.00M | $12.00M | -$65.00M | -$104.00M | -$694.00M | -$76.00M | -$70.00M | $9.00M |
| Income Before Taxes | $7.31B | $7.04B | $6.30B | $7.83B | $8.84B | $7.22B | $4.07B | $3.26B |
| Provision for Income Taxes | $547.00M | $657.00M | $284.00M | $703.00M | $1.11B | $850.00M | $374.00M | $324.00M |
| Net Income | $6.72B | $6.34B | $5.96B | $6.96B | $7.73B | $6.38B | $3.70B | — |
| Basic EPS | $17.77 | $16.58 | $15.52 | $17.75 | $19.62 | $16.09 | $9.24 | $7.31 |
| Diluted EPS | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 |
| Basic Shares Outstanding | 377.00M | 382.00M | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M |
| Diluted Shares Outstanding | 378.00M | 383.00M | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $25.13 | $25.01 | $25.21 | 12 | ↑1 ↓0 |
| Dec 2027 | $27.51 | $26.49 | $29.07 | 12 | ↑1 ↓0 |
| Dec 2028 | $30.01 | $28.83 | $31.71 | 6 | ↑0 ↓0 |
| Dec 2029 | $34.22 | $34.22 | $34.22 | 1 | ↑0 ↓0 |
